Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

The Clinical Trials Committee

  • Dr. Birgit Geoerger, Gustave Roussy, Villejuif, FR - Chair of the committee
  • Dr. Michela Casanova, Istituto Nazionale Tumori, Milan, IT
  • Prof. Andrew Pearson
  • Prof. François Doz, Institut Curie, Paris, FR
  • Dr. Darren Hargrave, GOSH, London, UK
  • Dr. Beate Wulff, University of Essen, Essen, GE
  • Dr. Lynley Marshall, Royal Marsden, London, UK
  • Dr. Nathalie Gaspar, Gustave Roussy, Villejuif, FR
  • Dr. Francis Mussai, Birmingham Children's Hospital, Birmingham, UK
  • Dr. Lucas Moreno, Hospital Infantil Nino Jesus, Madrid, SP
  • Prof. Andre Baruchel, Hopital Robert Debré, Paris, FR
  • Prof. Michel Zwaan, Erasmus MC, Rotterdam, NL
  • Dr. Xavier Paoletti, Gustave Roussy, Villejuif, FR

ITCC Clinical Trials Committee (CTC) main responsibilities consist of overseeing the ITCC clinical trials portfolio.


The committee provides expertise in pediatric new drug development and trial design possibly early in the trial development. It encourages and supports the development of various early clinical trials, First in Child, as well as disease specific and overarching trials. The current focus lies on translating biological findings into clinics and integrating epigenetic modulators and immune therapy within the current precision cancer medicine program. The CTC evaluates, reviews all trial protocols from both academic institutions and pharmaceutical companies for consistency with ITCC strategic aims. CTC approval of academic trials is fundamental for an academic sponsorship as well as funding support from the consortium supporting charities.